Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
REDWOOD CITY, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Jon Williams, Ph.D., as vice president, clinical affairs, effective immediately. Dr. Williams will provide scientific and technical expertise and leadership across Adverum’s clinical development program for ADVM-022, reporting to Julie Clark, M.D., chief medical off
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO -- -- Leone Patterson departs as president and CFO after five years of service -- REDWOOD CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Leone Patterson, president and chief financial officer, has resigned to pursue another opportunity. Christopher J.
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
Shares of developmental gene therapy company Adverum Biotechnologies (NASDAQ: ADVM) sank by 11.3% during the month of May, according to data provided by S&P Global Market Intelligence. In late April, Adverum announced that its experimental gene therapy for diabetic macular edema (DME), known as ADVM-022, hit a serious snag in its ongoing midstage trial. Specifically, a patient in the trial reportedly developed hypotony (low intraocular pressure) and loss of vision in the treated eye, forcing t...